NASDAQ:VIVO - Meridian Bioscience Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.50 +0.01 (+0.08 %) (As of 04/22/2019 02:11 AM ET)Previous Close$12.50Today's Range$12.38 - $12.5652-Week Range$12.30 - $19.84Volume176,964 shsAverage Volume447,597 shsMarket Capitalization$531.13 millionP/E Ratio16.89Dividend Yield4.00%Beta0.49 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. Meridian Bioscience, Inc. was founded in 1976 and is headquartered in Cincinnati, Ohio. Receive VIVO News and Ratings via Email Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:VIVO Previous Symbol CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone513-271-3700Debt Debt-to-Equity Ratio0.24 Current Ratio6.75 Quick Ratio4.72Price-To-Earnings Trailing P/E Ratio16.89 Forward P/E Ratio19.84 P/E GrowthN/A Sales & Book Value Annual Sales$213.57 million Price / Sales2.49 Cash Flow$0.9527 per share Price / Cash Flow13.12 Book Value$4.14 per share Price / Book3.02Profitability EPS (Most Recent Fiscal Year)$0.74 Net Income$23.84 million Net Margins12.06% Return on Equity19.17% Return on Assets13.36%Miscellaneous Employees585 Outstanding Shares42,490,000Market Cap$531.13 million Next Earnings Date4/30/2019 (Confirmed) OptionableOptionable Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions What is Meridian Bioscience's stock symbol? Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO." How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience? Meridian Bioscience declared a quarterly dividend on Friday, January 25th. Investors of record on Monday, February 4th will be paid a dividend of $0.125 per share on Thursday, February 14th. This represents a $0.50 annualized dividend and a yield of 4.00%. The ex-dividend date is Friday, February 1st. View Meridian Bioscience's Dividend History. How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) released its earnings results on Thursday, January, 24th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.02. The company earned $51.48 million during the quarter, compared to analysts' expectations of $51.50 million. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. Meridian Bioscience's revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.15 EPS. View Meridian Bioscience's Earnings History. When is Meridian Bioscience's next earnings date? Meridian Bioscience is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for Meridian Bioscience. What guidance has Meridian Bioscience issued on next quarter's earnings? Meridian Bioscience updated its FY19 earnings guidance on Thursday, January, 24th. The company provided earnings per share (EPS) guidance of $0.74-0.76 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.76. The company issued revenue guidance of $214-218 million (Flat to +2%), compared to the consensus revenue estimate of $221.13 million.Meridian Bioscience also updated its FY 2019 guidance to $0.74-0.76 EPS. What price target have analysts set for VIVO? 3 brokerages have issued twelve-month price objectives for Meridian Bioscience's shares. Their forecasts range from $11.00 to $15.00. On average, they expect Meridian Bioscience's share price to reach $13.3333 in the next year. This suggests a possible upside of 6.7% from the stock's current price. View Analyst Price Targets for Meridian Bioscience. What is the consensus analysts' recommendation for Meridian Bioscience? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 2 sell ratings and 1 hold rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Meridian Bioscience. Has Meridian Bioscience been receiving favorable news coverage? News headlines about VIVO stock have trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Meridian Bioscience earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. Who are some of Meridian Bioscience's key competitors? Some companies that are related to Meridian Bioscience include Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER) and Arca Biopharma (ABIO). What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include General Electric (GE), Cara Therapeutics (CARA), Exelixis (EXEL), Amicus Therapeutics (FOLD), Advanced Micro Devices (AMD), Cronos Group (CRON), GW Pharmaceuticals PLC- (GWPH), Procter & Gamble (PG), Amgen (AMGN) and Catalyst Pharmaceuticals (CPRX). Who are Meridian Bioscience's key executives? Meridian Bioscience's management team includes the folowing people: Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 50)Mr. Lawrence J. Baldini, Exec. VP of Global Operations (Age 60)Ms. Susan D. Rolih, Consultant (Age 70)Ms. Melissa A. Lueke, Consultant (Age 56)Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51) Who are Meridian Bioscience's major shareholders? Meridian Bioscience's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ronna Sue Cohen (1.33%), 6 Meridian (0.10%), Ronna Sue Cohen (0.08%), Cardinal Capital Management (0.07%), Nisa Investment Advisors LLC (0.06%) and First Manhattan Co. (0.01%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience. Which institutional investors are selling Meridian Bioscience stock? VIVO stock was sold by a variety of institutional investors in the last quarter, including Ronna Sue Cohen and First Manhattan Co.. View Insider Buying and Selling for Meridian Bioscience. Which institutional investors are buying Meridian Bioscience stock? VIVO stock was purchased by a variety of institutional investors in the last quarter, including Ronna Sue Cohen, 6 Meridian, Cardinal Capital Management, Nisa Investment Advisors LLC and Meeder Asset Management Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice and John Mcilwraith. View Insider Buying and Selling for Meridian Bioscience. How do I buy shares of Meridian Bioscience? Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Meridian Bioscience's stock price today? One share of VIVO stock can currently be purchased for approximately $12.50. How big of a company is Meridian Bioscience? Meridian Bioscience has a market capitalization of $531.13 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe. What is Meridian Bioscience's official website? The official website for Meridian Bioscience is http://www.meridianbioscience.com. How can I contact Meridian Bioscience? Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700. MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)Community Ranking: 1.9 out of 5 ()Outperform Votes: 225 (Vote Outperform)Underperform Votes: 363 (Vote Underperform)Total Votes: 588MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/22/2019 by MarketBeat.com StaffFeatured Article: What is the price-to-earnings growth (PEG) ratio?